SGLT-2 Inhibitors for Non-Alcoholic Fatty Liver Disease: A Review

Rong Xu; Difei Lian; Yan Xie; Zhilei Chen; Yan Wang; Lin Mu; Yuan Wang; Baoyu Zhang

doi:10.31083/j.fbl2807134

Frontiers in Bioscience-Landmark (Jul 2023)

SGLT-2 Inhibitors for Non-Alcoholic Fatty Liver Disease: A Review

Rong Xu,
Difei Lian,
Yan Xie,
Zhilei Chen,
Yan Wang,
Lin Mu,
Yuan Wang,
Baoyu Zhang

Affiliations

Rong Xu: Center for Endocrine Metabolism and Immune Diseases, Lu He Hospital, Capital Medical University, 100000 Beijing, China
Difei Lian: Center for Endocrine Metabolism and Immune Diseases, Lu He Hospital, Capital Medical University, 100000 Beijing, China
Yan Xie: Center for Endocrine Metabolism and Immune Diseases, Lu He Hospital, Capital Medical University, 100000 Beijing, China
Zhilei Chen: Center for Endocrine Metabolism and Immune Diseases, Lu He Hospital, Capital Medical University, 100000 Beijing, China
Yan Wang: Center for Endocrine Metabolism and Immune Diseases, Lu He Hospital, Capital Medical University, 100000 Beijing, China
Lin Mu: Center for Endocrine Metabolism and Immune Diseases, Lu He Hospital, Capital Medical University, 100000 Beijing, China
Yuan Wang: Center for Endocrine Metabolism and Immune Diseases, Lu He Hospital, Capital Medical University, 100000 Beijing, China
Baoyu Zhang: Center for Endocrine Metabolism and Immune Diseases, Lu He Hospital, Capital Medical University, 100000 Beijing, China

DOI: https://doi.org/10.31083/j.fbl2807134
Journal volume & issue: Vol. 28, no. 7
p. 134

Abstract

Read online

Non-alcoholic fatty liver disease (NAFLD) is a group of metabolic liver illnesses that lead to accumulation of liver fat mainly due to excessive nutrition. It is closely related to insulin resistance, obesity, type 2 diabetes, and cardiovascular disease, and has become one of the main causes of chronic liver disease worldwide. At present, there is no specific drug for the treatment of NAFLD; lifestyle interventions including dietary control and exercise are recommended as routine treatments. As a drug for the treatment of type 2 diabetes, sodium-glucose co-transporter type 2 (SGLT-2) inhibitors may also play a beneficial role in the treatment of NAFLD. This article reviews the mechanism of SGLT-2 inhibitors in the treatment of NAFLD.

Published in Frontiers in Bioscience-Landmark

ISSN: 2768-6701 (Print); 2768-6698 (Online)
Publisher: IMR Press
Country of publisher: Singapore
LCC subjects: Science: Chemistry: Organic chemistry: Biochemistry; Science: Biology (General)
Website: https://www.imrpress.com/journal/FBL

About the journal

Abstract

Keywords